Generation of MicroRNA-34 Sponges and Tough Decoys for the Heart: Developments and Challenges
Open Access
- 21 September 2018
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 9, 1090
Abstract
Heart failure (HF) is a debilitating and deadly chronic disease, with almost 50% of patients with HF dying within 5 years of diagnosis. With limited effective therapies to treat or cure HF, new therapies are greatly needed. microRNAs (miRNAs) are small non-coding RNA molecules that are powerful regulators of gene expression and play a key role in almost every biological process. Disruptions in miRNA gene expression has been functionally linked to numerous diseases, including cardiovascular disease. Molecular tools for manipulating miRNA activity have been developed, and there is evidence from preclinical studies demonstrating the potential of miRNAs to be therapeutic targets for cardiovascular disease. For clinical application, miRNA sponges and tough decoys have been developed for more stable suppression and targeted delivery of the miRNA of choice. The aim of this study was to generate miRNA sponges and tough decoys to target miR-34 in the mouse heart. We present data to show that using both approaches we were unable to get significant knockdown of miR-34 or regulate miR-34 target genes in the heart in vivo. We also review recent applications of this method in the heart and discuss further considerations for optimisation in construct design and testing, and the obstacles to be overcome before they enter the clinic.Keywords
This publication has 68 references indexed in Scilit:
- Cardiac regenerative medicine: At the crossroad of microRNA function and biotechnologyNon-coding RNA Research, 2017
- Bioinspired Negatively Charged Calcium Phosphate Nanocarriers for Cardiac Delivery of MicroRNAsNanomedicine, 2016
- miRNA Therapeutics: A New Class of Drugs with Potential Therapeutic Applications in the HeartFuture Medicinal Chemistry, 2015
- The war against heart failure: the Lancet lectureThe Lancet, 2015
- Adeno-Associated Virus-Mediated MicroRNA Delivery and TherapeuticsSeminars in Liver Disease, 2015
- The Therapeutic Potential of Mirnas Regulated in Settings of Physiological Cardiac HypertrophyFuture Medicinal Chemistry, 2014
- miR-206 Represses Hypertrophy of Myogenic Cells but Not Muscle Fibers via Inhibition of HDAC4PLOS ONE, 2013
- Long-term, efficient inhibition of microRNA function in mice using rAAV vectorsNature Methods, 2012
- Pervasive roles of microRNAs in cardiovascular biologyNature, 2011
- Improved cardiac gene transfer by transcriptional and transductional targeting of adeno-associated viral vectorsCardiovascular Research, 2006